Federal Advocacy

After months of uncertainty for startups and technology innovators across the country, the U.S. Senate has passed bipartisan legislation, S....

The bipartisan House BIOtech Caucus recently announced its first-ever legislative endorsements, backing two bills aimed at strengthening U.S....

As Congress considers whether to codify Most Favored Nation (MFN) drug pricing into statute, recent comments by CMS Administrator Dr. Mehmet Oz...

The U.S. Food and Drug Administration (FDA) has announced a significant shift in its drug approval standards, moving away from the long-standing...

The January 30, 2026 announcement of a Unified NIH Funding Strategy marks one of the most consequential shifts in federal biomedical research...

National Institutes of Health (NIH) Director Dr. Jayanta “Jay” Bhattacharya faced a pointed round of bipartisan scrutiny at a Senate...

In overlapping victories for biotech innovation and public health, the U.S. Senate and House of Representatives have approved two landmark pieces...

A sweeping government funding package now before the U.S. Senate carries major implications for the life sciences sector - touching drug...

The recent White House announcement of “The Great Healthcare Plan” landed with familiar fanfare: bold promises to lower drug prices,...

A coalition of life sciences investors, Incubate, says capital is beginning to flow back into rare disease drug development, citing more than $1...

This month, the U.S. Food and Drug Administration (FDA) took a notable step toward modernizing oversight of digital health technologies -...

The U.S. Department of Health and Human Services (HHS) has formally lent its support to the Give Kids A Chance Act - landmark legislation...